Running a Depo-Provera / Meningioma Campaign
MTAA's Depo-Provera / Meningioma campaigns follow the four-phase methodology developed across $250M+ in managed mass tort ad spend. Every campaign begins with a Jacob Score evaluation — assessing causation confidence, MDL momentum, the current entry window, and competitive advertising environment before any budget is committed.
Creative Approach
MTAA deploys both Harvey (anger/outrage energy) and Mae (empathy/connection) creative registers simultaneously for Depo-Provera / Meningioma campaigns. Meta's Andromeda engine routes each creative to the sub-audience it resonates with — maximizing qualified claimant self-identification across the eligible population.
Intake Qualification
All Depo-Provera / Meningioma inbound traffic routes through CloudIntake, MTAA's dedicated mass tort call center. Claimants are screened against current legal eligibility criteria and signed via e-signature. The signed retainer Purchase event feeds back to Meta, training the algorithm to find better-qualified future claimants.
Campaign Window Status
Current Jacob Score for Depo-Provera / Meningioma: 72/100 (PROVEN). Window status: CAMPAIGN OPEN. Full intelligence available on TortIntel.ai — including causation science summary, defendant matrix, litigation timeline, and live signal feed.
Work With MTAA on Depo-Provera / Meningioma
MTAA manages Depo-Provera / Meningioma campaigns under the standard 15% management fee model — no lead markups, no cost-per-case inflation. CloudIntake delivers signed retainers, not raw leads. Campaigns can launch within 48 hours of onboarding.